GOVX vs. HOWL, OPTN, VTVT, IMRX, KRON, ACHL, UNCY, ALXO, PRLD, and IMMX
Should you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Werewolf Therapeutics (HOWL), OptiNose (OPTN), vTv Therapeutics (VTVT), Immuneering (IMRX), Kronos Bio (KRON), Achilles Therapeutics (ACHL), Unicycive Therapeutics (UNCY), ALX Oncology (ALXO), Prelude Therapeutics (PRLD), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.
GeoVax Labs vs.
GeoVax Labs (NASDAQ:GOVX) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk, community ranking and profitability.
GeoVax Labs has a beta of 3.28, suggesting that its stock price is 228% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500.
In the previous week, GeoVax Labs had 1 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 1 mentions for GeoVax Labs and 0 mentions for Werewolf Therapeutics. GeoVax Labs' average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score.
Werewolf Therapeutics received 8 more outperform votes than GeoVax Labs when rated by MarketBeat users. However, 96.00% of users gave GeoVax Labs an outperform vote while only 69.57% of users gave Werewolf Therapeutics an outperform vote.
6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 5.7% of GeoVax Labs shares are held by insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
GeoVax Labs has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Werewolf Therapeutics' return on equity of -58.83% beat GeoVax Labs' return on equity.
GeoVax Labs has higher earnings, but lower revenue than Werewolf Therapeutics.
GeoVax Labs presently has a consensus target price of $14.20, suggesting a potential upside of 721.33%. Werewolf Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 554.97%. Given GeoVax Labs' stronger consensus rating and higher probable upside, research analysts plainly believe GeoVax Labs is more favorable than Werewolf Therapeutics.
Summary
GeoVax Labs beats Werewolf Therapeutics on 10 of the 16 factors compared between the two stocks.
Get GeoVax Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
GeoVax Labs Competitors List
Related Companies and Tools
This page (NASDAQ:GOVX) was last updated on 2/19/2025 by MarketBeat.com Staff